技術轉移招商en文章 – Page 2 – 【國家衛生研究院】技轉及育成中心

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17

Uncategorized / 2020 年 8 月 18 日 2021 年 9 月 2 日

Subject NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). Description The Technology is to use induced stem cell-derived exosomes, instead of stem cells, as regeneration medicine. The invention is a method of inducing stem cells to release exosomes carrying essential molecules for the …

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17 Read More »

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020)

Uncategorized / 2020 年 7 月 20 日 2021 年 9 月 2 日

1.Title “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing. 2.Description: The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized by using ketamine in combination …

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章, 技術轉移招商en文章, 產學研發徵求夥伴en文章 / 2020 年 4 月 16 日 2021 年 9 月 2 日

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed are culturing methods for growing the NHRI sMDCK cell line and methods for producing a vaccine from the MDCK cell line grown in the chemically defined medium. Traditionally, cell lines, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16) Read More »

NHRI technology, “Influenza vaccine production using suspension MDCK (NHRI sMDCK) cells” (abbreviated as “The Technology”) available for technology licensing. (2020/04/15)

Uncategorized / 2020 年 4 月 15 日 2021 年 9 月 2 日

NHRI technology, “Influenza vaccine production using suspension MDCK (NHRI sMDCK) cells” (abbreviated as “The Technology”) available for technology licensing. (2020/04/15) Read More »

NHRI technology, “Influenza vaccine production using suspension MDCK (NHRI sMDCK) cells” (abbreviated as “The Technology”) available for technology licensing.(2019/12/4)

Uncategorized / 2019 年 12 月 4 日 2021 年 9 月 2 日

NHRI technology, “Influenza vaccine production using suspension MDCK (NHRI sMDCK) cells” (abbreviated as “The Technology”) available for technology licensing.(2019/12/4) Read More »